Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Comments
Loading...
Twist Bioscience Analyst Ratings and Price Targets | NASDAQ:TWST | Benzinga
Twist Bioscience Corp has a consensus price target of $44.93 based on the ratings of 14 analysts. The high is $62 issued by Scotiabank on February 4, 2025. The low is $27 issued by Berenberg on September 27, 2023. The 3 most-recent analyst ratings were released by Goldman Sachs, Guggenheim, and Baird on May 6, 2025, respectively. With an average price target of $47.33 between Goldman Sachs, Guggenheim, and Baird, there's an implied 54.05% upside for Twist Bioscience Corp from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Goldman Sachs
Guggenheim
Baird
JP Morgan
Barclays
1calculated from analyst ratings
Analyst Ratings for Twist Bioscience
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/06/2025 | Buy Now | 56.22% | Goldman Sachs | Matthew Sykes62% | $55 → $48 | Maintains | Buy | Get Alert |
| 05/06/2025 | Buy Now | 62.73% | Guggenheim | Subbu Nambi42% | $50 → $50 | Reiterates | Buy → Buy | Get Alert |
| 05/06/2025 | Buy Now | 43.21% | Baird | Catherine Ramsey50% | $54 → $44 | Maintains | Outperform | Get Alert |
| 05/06/2025 | Buy Now | 7.4% | JP Morgan | Rachel Vatnsdal65% | $40 → $33 | Maintains | Underweight | Get Alert |
| 04/10/2025 | Buy Now | 46.46% | Barclays | Luke Sergott50% | $58 → $45 | Maintains | Overweight | Get Alert |
| 02/04/2025 | Buy Now | 101.79% | Scotiabank | Sung Ji Nam44% | $54 → $62 | Maintains | Sector Outperform | Get Alert |
| 02/04/2025 | Buy Now | 30.19% | JP Morgan | Rachel Vatnsdal65% | $35 → $40 | Maintains | Underweight | Get Alert |
| 02/04/2025 | Buy Now | 75.75% | Baird | Catherine Ramsey50% | $48 → $54 | Maintains | Outperform | Get Alert |
| 12/13/2024 | Buy Now | 95.28% | Wolfe Research | Doug Schenkel72% | → $60 | Initiates | → Outperform | Get Alert |
| 11/26/2024 | Buy Now | 88.77% | TD Cowen | Steven Mah51% | $58 → $58 | Reiterates | Buy → Buy | Get Alert |
| 11/19/2024 | Buy Now | 69.24% | Barclays | Luke Sergott50% | $55 → $52 | Maintains | Overweight | Get Alert |
| 11/19/2024 | Buy Now | 75.75% | Scotiabank | Sung Ji Nam44% | $50 → $54 | Maintains | Sector Outperform | Get Alert |
| 11/19/2024 | Buy Now | 56.22% | Baird | Catherine Ramsey50% | $46 → $48 | Maintains | Outperform | Get Alert |
| 10/17/2024 | Buy Now | 56.22% | Leerink Partners | — | $45 → $48 | Maintains | Market Perform | Get Alert |
| 10/01/2024 | Buy Now | 82.26% | Evercore ISI Group | Vijay Kumar52% | $52 → $56 | Maintains | Outperform | Get Alert |
| 08/05/2024 | Buy Now | 79.01% | Barclays | Luke Sergott50% | $60 → $55 | Maintains | Overweight | Get Alert |
| 08/05/2024 | Buy Now | 13.91% | JP Morgan | Tycho Peterson83% | $28 → $35 | Maintains | Underweight | Get Alert |
| 08/05/2024 | Buy Now | 49.72% | Baird | Catherine Ramsey50% | $40 → $46 | Maintains | Outperform | Get Alert |
| 07/09/2024 | Buy Now | 79.01% | Goldman Sachs | Matthew Sykes62% | $45 → $55 | Maintains | Buy | Get Alert |
| 06/28/2024 | Buy Now | 95.28% | Barclays | Luke Sergott50% | $45 → $60 | Maintains | Overweight | Get Alert |
| 06/13/2024 | Buy Now | 111.55% | TD Cowen | Steven Mah51% | $55 → $65 | Maintains | Buy | Get Alert |
| 06/05/2024 | Buy Now | 72.5% | Guggenheim | Subbu Nambi42% | → $53 | Initiates | → Buy | Get Alert |
| 05/06/2024 | Buy Now | 56.22% | Scotiabank | Sung Ji Nam44% | $43 → $48 | Maintains | Sector Outperform | Get Alert |
| 05/03/2024 | Buy Now | 62.73% | Evercore ISI Group | Vijay Kumar52% | $46 → $50 | Maintains | Outperform | Get Alert |
| 05/03/2024 | Buy Now | 46.46% | Barclays | Luke Sergott50% | $40 → $45 | Maintains | Overweight | Get Alert |
| 05/03/2024 | Buy Now | 30.19% | Baird | Catherine Ramsey50% | $39 → $40 | Maintains | Outperform | Get Alert |
| 04/10/2024 | Buy Now | 30.19% | Barclays | Luke Sergott50% | $45 → $40 | Maintains | Overweight | Get Alert |
| 02/05/2024 | Buy Now | 39.95% | Scotiabank | Sung Ji Nam44% | $30 → $43 | Maintains | Sector Outperform | Get Alert |
| 01/25/2024 | Buy Now | 46.46% | Barclays | Luke Sergott50% | $30 → $45 | Maintains | Overweight | Get Alert |
| 01/18/2024 | Buy Now | 46.46% | Goldman Sachs | Matthew Sykes62% | $25 → $45 | Maintains | Buy | Get Alert |
| 01/17/2024 | Buy Now | 46.46% | Goldman Sachs | Matthew Sykes62% | $25 → $45 | Upgrade | Neutral → Buy | Get Alert |
| 09/27/2023 | Buy Now | -12.12% | Berenberg | Gaurav Goparaju27% | → $27 | Initiates | → Buy | Get Alert |
| 08/07/2023 | Buy Now | -15.38% | Barclays | Luke Sergott50% | $20 → $26 | Maintains | Overweight | Get Alert |
| 07/13/2023 | Buy Now | -34.91% | Goldman Sachs | Matthew Sykes62% | $18 → $20 | Maintains | Neutral | Get Alert |
| 05/08/2023 | Buy Now | -41.42% | Baird | Catherine Ramsey50% | $29 → $18 | Maintains | Outperform | Get Alert |
| 05/08/2023 | Buy Now | -34.91% | Barclays | Luke Sergott50% | $32 → $20 | Maintains | Overweight | Get Alert |
| 04/19/2023 | Buy Now | -34.91% | Goldman Sachs | Matthew Sykes62% | $43 → $20 | Maintains | Neutral | Get Alert |
| 04/18/2023 | Buy Now | -34.91% | Goldman Sachs | Matthew Sykes62% | $43 → $20 | Maintains | Neutral | Get Alert |
| 02/06/2023 | Buy Now | 39.95% | Goldman Sachs | Matthew Sykes62% | $50 → $43 | Maintains | Neutral | Get Alert |
| 02/06/2023 | Buy Now | -5.61% | Baird | Catherine Ramsey50% | $33 → $29 | Maintains | Outperform | Get Alert |
| 02/06/2023 | Buy Now | 4.15% | Barclays | Luke Sergott50% | $37 → $32 | Maintains | Overweight | Get Alert |
| 01/30/2023 | Buy Now | 20.42% | Barclays | Luke Sergott50% | $43 → $37 | Maintains | Overweight | Get Alert |
| 01/05/2023 | Buy Now | 7.4% | Scotiabank | Sung Ji Nam44% | → $33 | Initiates | → Sector Outperform | Get Alert |
| 01/03/2023 | Buy Now | 17.17% | Evercore ISI Group | Vijay Kumar52% | $28 → $36 | Upgrade | In-Line → Outperform | Get Alert |
| 11/21/2022 | Buy Now | 7.4% | Baird | Catherine Schulte66% | $56 → $33 | Maintains | Outperform | Get Alert |
| 11/21/2022 | Buy Now | 39.95% | Barclays | Luke Sergott50% | $45 → $43 | Maintains | Overweight | Get Alert |
| 11/21/2022 | Buy Now | -2.36% | SVB Leerink | Puneet Souda56% | $45 → $30 | Maintains | Market Perform | Get Alert |
| 10/07/2022 | Buy Now | 46.46% | SVB Leerink | Puneet Souda56% | $50 → $45 | Maintains | Market Perform | Get Alert |
| 10/06/2022 | Buy Now | 46.46% | Barclays | Luke Sergott50% | $55 → $45 | Maintains | Overweight | Get Alert |
| 08/08/2022 | Buy Now | 79.01% | Barclays | Luke Sergott50% | $45 → $55 | Maintains | Overweight | Get Alert |
| 08/08/2022 | Buy Now | 62.73% | SVB Leerink | Puneet Souda56% | $45 → $50 | Maintains | Market Perform | Get Alert |
| 07/13/2022 | Buy Now | 46.46% | Barclays | Luke Sergott50% | $40 → $45 | Maintains | Overweight | Get Alert |
FAQ
What is the target price for Twist Bioscience (TWST) stock?
The latest price target for Twist Bioscience (NASDAQ:TWST) was reported by Goldman Sachs on May 6, 2025. The analyst firm set a price target for $48.00 expecting TWST to rise to within 12 months (a possible 56.22% upside). 22 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Twist Bioscience (TWST)?
The latest analyst rating for Twist Bioscience (NASDAQ:TWST) was provided by Goldman Sachs, and Twist Bioscience maintained their buy rating.
When was the last upgrade for Twist Bioscience (TWST)?
The last upgrade for Twist Bioscience Corp happened on January 17, 2024 when Goldman Sachs raised their price target to $45. Goldman Sachs previously had a neutral for Twist Bioscience Corp.
When was the last downgrade for Twist Bioscience (TWST)?
There is no last downgrade for Twist Bioscience.
When is the next analyst rating going to be posted or updated for Twist Bioscience (TWST)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Twist Bioscience, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Twist Bioscience was filed on May 6, 2025 so you should expect the next rating to be made available sometime around May 6, 2026.
Is the Analyst Rating Twist Bioscience (TWST) correct?
While ratings are subjective and will change, the latest Twist Bioscience (TWST) rating was a maintained with a price target of $55.00 to $48.00. The current price Twist Bioscience (TWST) is trading at is $30.73, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
